AbbVie’s Dual Regimen Receives EC’s Approval for Patients with Previously Untreated Chronic Lymphocytic Leukemia

 AbbVie’s Dual Regimen Receives EC’s Approval for Patients with Previously Untreated Chronic Lymphocytic Leukemia

AbbVie’s Dual Regimen Receives EC’s Approval for Patients with Previously Untreated Chronic Lymphocytic Leukemia

Shots:

  • The approval is based on P-III CLL14 study assessing Venclyxto (venetoclax) + obinutuzumab vs obinutuzumab + chlorambucil in 432 patients with previously untreated CLL and coexisting medical condition
  • The P-III CLL14 study results: median follow up @28mos. superior PFS; @40mos. median PFS had not been reached (35.6mos.); @36mos. PFS (81.9% vs 49.5%) @1yr. patients experienced deep response as measured by higher rates of undetectable MRD or CR
  • Venclyxto is a first-in-class therapy targeting BCL-2 protein and works to restore the process of apoptosis and has received a CHMP’s positive opinion for MAA in combination with obinutuzumab to treat CLL in Jan’2020

Click here ­to­ read full press release/ article | Ref: AbbVie | Image: StraitTimes

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post